10-Q: Codexis Reports Q1 2026 Results, Revenue Doubles

Codexis, Inc. announced its first quarter 2026 financial results, reporting a significant increase in total revenues driven by strong growth in research and development revenue.

Summary

• Codexis, Inc. reported total revenues of $15.2 million for the three months ended March 31, 2026, a 102% increase compared to $7.5 million in the same period of 2025.
• Product revenue grew 19% to $7.2 million, while research and development revenue surged by 443% to $8.1 million.
• The company reported a net loss of $8.7 million for the quarter, an improvement from a net loss of $20.7 million in the prior year's quarter.
• Operating expenses decreased by 17% to $23.3 million, primarily due to reductions in research and development and selling, general, and administrative expenses.
• Cash and cash equivalents decreased to $36.6 million from $50.8 million at the end of 2025, while working capital stood at $64.8 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with significant revenue growth and a substantially reduced net loss, indicating improved operational efficiency and strong demand for its R&D services, although continued losses and reliance on key customers present ongoing risks.

Positives

• Total revenues more than doubled, increasing by 102% to $15.2 million.
• Research and development revenue saw a substantial increase of 443% to $8.1 million, largely due to the recognition of deferred revenue from a licensing agreement with Merck.
• Product revenue increased by 19% to $7.2 million.
• Net loss significantly decreased by 58% to $8.7 million, compared to $20.7 million in the prior year.
• Total costs and operating expenses decreased by 17% to $23.3 million.
• Product gross margin improved to 71% from 55% in the prior year, indicating a shift towards more profitable products.
• The company believes its existing cash and cash equivalents, combined with expected revenues and expense management, will provide adequate funds for at least the next 12 months.

Negatives

• The company continues to incur net losses, with an accumulated deficit of $615.5 million as of March 31, 2026.
• Cash and cash equivalents decreased by $14.2 million during the quarter, ending at $36.6 million.
• The company is dependent on a limited number of key customers, with 64% of total revenues in the quarter coming from customers representing 10% or more of revenue.
• The company relies on third-party contract manufacturers for large-scale production of its enzymes, posing supply chain risks.
• The company has a history of net losses and may not achieve or maintain profitability.

Risks

• The company has a history of net losses and may not achieve or maintain profitability.
• The company has invested significant resources in novel, largely unproven technologies like enzymatic nucleic acid synthesis, and failure to validate performance at scale or gain regulatory acceptance could impede customer adoption.
• Therapeutics development programs are highly regulated and expensive, and the success of customer product candidates utilizing Codexis' enzymes is uncertain.
• The company is dependent on a limited number of customers, and the loss or reduction of business from a significant customer could materially adversely affect revenues.
• Some product supply agreements have finite durations and may not be extended or renewed, and generally do not require customers to purchase specific quantities.
• The demand for products depends on customers' research and development and the clinical and market success of their products.
• The company relies on third-party contract manufacturers for large-scale production, and any issues with these manufacturers could adversely impact product availability and sales.
• The company's ECO Synthesis manufacturing platform is novel and has not yet been commercialized, facing potential unforeseen results, delays, and setbacks.
• Third parties may claim infringement of their intellectual property rights, leading to costly litigation.
• The company uses hazardous materials and must comply with environmental laws and regulations, with potential liability for improper handling or disposal.
• The company may need additional capital in the future to expand its business, and future financings may involve equity issuance, leading to dilution.

Future Outlook

The company believes its existing cash and cash equivalents, combined with future expectations for product revenues, research and development revenue, and expense management, will provide adequate funds for planned ongoing operations, capital expenditures, and working capital requirements for at least the next 12 months. However, they may need additional capital if current plans and assumptions change or for strategic reasons.

Management Comments

• The company expects to advance at least one of its partnerships with CDMOs, including initiating a technology transfer, in 2026.
• The company expects to expand its enzymatic tools and process offerings as it further enhances the ECO Synthesis platform to address market needs for scalable and sustainable RNAi manufacturing.
• The company believes its relationships with CDMOs are a vital extension of its strategy to be a technology solutions provider.

Industry Context

StockSavvy.ai notes that Codexis' significant revenue growth, particularly in R&D revenue, highlights the increasing demand for specialized enzyme technology in biopharmaceutical manufacturing, especially for novel modalities like RNAi therapeutics. The company's focus on its ECO Synthesis platform and partnerships with CDMOs positions it within a competitive but growing segment of the life sciences industry.

Comparison to Industry Standards

• Codexis' product gross margin of 71% for Q1 2026 is an improvement from 55% in Q1 2025, suggesting better product mix or cost management. This margin should be compared to industry benchmarks for enzyme manufacturers and CDMOs, which can vary widely based on product complexity and scale.
• The company's net loss of $8.7 million in Q1 2026, while still a loss, represents a significant reduction from $20.7 million in Q1 2025. This improved performance, driven by increased revenue and decreased operating expenses, is a positive step towards profitability, a key metric for companies in the biotechnology and pharmaceutical services sector.
• The company's strategy of partnering with large-scale CDMOs to evaluate its ECO platform for GMP-grade siRNA drug substance aligns with industry trends where specialized technology providers collaborate with established manufacturers to achieve scale and regulatory compliance. Competitors like Agilent Technologies and other CDMOs are also investing in RNA manufacturing capabilities.

Legal Proceedings

• The company is not currently a party to any material pending litigation or other material legal proceedings.

Stakeholder Impact

• Shareholders: Potential for increased share value due to revenue growth and reduced losses, but ongoing net losses and potential dilution from future capital raises remain concerns.
• Employees: Continued investment in technology development and potential for growth may offer job security and opportunities, but cost-saving measures like headcount reduction could impact morale.
• Customers: Access to advanced enzyme technology for therapeutics manufacturing, with potential for improved yields and efficiency. Partnerships with CDMOs aim to provide seamless scale-up.
• Creditors: The company is in compliance with covenants under its Innovatus Loan Agreement, but the loan is secured by substantially all assets, posing a risk in case of default.

Next Steps

• Advance at least one partnership with a CDMO, including initiating technology transfer, in 2026.
• Expand enzymatic tools and process offerings for the ECO Synthesis platform.
• Continue to manage cash usage and investment of liquid cash to meet working capital needs.
• Potentially seek additional capital through equity offerings, debt financings, or collaborations.

Key Dates

Recommendation

The company shows strong revenue growth and improved loss reduction, driven by its technology platform and strategic partnerships. However, the continued net losses, significant accumulated deficit, and reliance on a few key customers warrant a cautious 'hold' rating. Further progress towards profitability and diversification of revenue streams would be needed to justify a stronger recommendation.

Keywords

Codexis, Form 10-Q, Quarterly Report, Enzymes, Biocatalysis, ECO Synthesis, RNAi Therapeutics, Drug Manufacturing, Financial Results, SEC Filing